Blocked Randomized Controlled Trial
- Introduced by
- R. A. Fisher (blocking principle); systematic RCT application by Bradford Hill and later Pocock, Friedman et al.
- Year
- 1920s (Fisher's blocking principle); applied to RCTs from the 1940s onward
- Type
- Experimental design
- Family
- Experimental design
What does it do?
A blocked randomized controlled trial (blocked RCT) uses permuted-block randomization to ensure that treatment groups remain balanced in size — and optionally in key characteristics — throughout recruitment.
Within each block of fixed or randomly varied size, all treatment allocations are present in equal numbers, so imbalance cannot accumulate even if the trial is stopped early. This makes blocked RCTs the standard randomization approach in clinical and behavioral intervention research.
The intuition behind the method
Imagine enrolling 100 patients one by one. Pure randomization might, by chance, assign the first 20 patients mostly to one arm, distorting interim looks and final comparisons. Blocking prevents this: the researcher pre-specifies small blocks of, say, four slots (two per arm), so every four consecutive enrollments restore balance. The treatment group sizes stay close to equal throughout the trial. If blocks also correspond to sites or strata, balance is maintained across those subgroups as well, protecting the study against the confounding that uneven enrollment can introduce.
History
The principle of blocking originated with R. A. Fisher's agricultural field experiments in the 1920s, where plots were grouped into blocks to control soil variability. Bradford Hill applied randomization to clinical trials in the landmark 1948 streptomycin tuberculosis trial. Permuted-block randomization for RCTs was systematically described and advocated by Stuart Pocock in his 1983 textbook and by Friedman, Furberg, and DeMets in successive editions of Fundamentals of Clinical Trials. It is now the de facto standard in most phase II and phase III clinical trials.
When to use it
Use a blocked RCT when you need to compare two or more interventions under controlled conditions and want to guarantee near-equal group sizes throughout recruitment — essential when interim analyses or early stopping are planned. Blocking is particularly valuable in multi-site trials, where separate block sequences per site prevent site-level confounding. Do not use a simple blocked (unstratified) RCT when important prognostic covariates vary sharply across recruitment sites or time; stratified blocking or minimization is preferable then. Avoid blocked randomization in very small trials (n < 20) if blocks are fixed and the block size is known, because late-enrollment allocation becomes predictable even with concealment measures.
Limitations and considerations
- Fixed block sizes can allow prediction of allocation near the end of each block if the randomization is not fully concealed, introducing selection bias.
- Does not completely eliminate covariate imbalance — only enforces balance on stratification variables explicitly incorporated into the design.
- Stratifying on too many variables simultaneously creates an unmanageable number of small strata, defeating the purpose of blocking.
- Analysis must account for the blocking structure; ignoring stratification variables in the model can reduce statistical efficiency.
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Guarantees approximate balance in group sizes at any point during recruitment, protecting interim analyses.
- Reduces random chance imbalance on measured and unmeasured baseline covariates compared with simple randomization.
- Compatible with stratification, allowing simultaneous balance on multiple key prognostic factors.
- Widely accepted regulatory standard; well understood by statisticians, reviewers, and ethics boards.
- Random block-size variation effectively prevents allocation prediction even when block size is approximately known.
Applications
- Phase II and III pharmaceutical trials requiring regulatory-grade randomization with interim analyses.
- Multi-site educational or behavioral intervention studies where site is a known source of variability.
- Surgical or procedural trials where patient volume and case-mix differ substantially across centers.
- Rehabilitation and physiotherapy RCTs where therapist or clinic effects must be balanced across arms.
- Vaccine efficacy trials stratified by age group or serological status at enrollment.
How it works
How it works
The investigator chooses a block size (commonly 4, 6, or a randomly varying sequence of sizes to prevent allocation prediction). If stratification is planned, blocks are defined separately within each stratum — for example, separately by site, sex, or baseline severity — so that balance is enforced within every subgroup of interest.
For each block, all permutations of the treatment labels that satisfy the target allocation ratio are listed (e.g., for a 1:1 ratio in blocks of 4: AABB, ABAB, ABBA, etc.), and one permutation is selected at random using a computer random-number generator. Concatenating the permutations for successive blocks produces the full allocation sequence.
As participants are enrolled and meet eligibility criteria, they are assigned the next allocation in the sequence. Concealment is critical: the sequence must be stored securely (e.g., sealed envelopes or a central randomization system) so that neither recruiter nor participant can predict the next assignment. Foreknowledge of the allocation breaks blinding and introduces selection bias.
Experimental and control interventions are administered according to the trial protocol. Blinding of participants, care providers, and outcome assessors is maintained to the degree feasible. Treatment fidelity is monitored to ensure that the intervention is delivered as intended in all arms.
Primary and secondary outcomes are analyzed according to the pre-specified statistical analysis plan, typically using analysis of covariance (ANCOVA), mixed models for repeated measures, or logistic regression, with adjustment for any stratification variables used in the randomization. Intention-to-treat analysis is the primary estimand; per-protocol analyses are secondary.
Common pitfalls
- Using fixed block sizes with an open (unblinded) allocation list — even sophisticated recruiters can deduce the next assignment, violating concealment and introducing selection bias.
- Stratifying on too many variables: with k binary strata variables, the number of strata is 2^k; with small sample sizes most strata will be near-empty, providing no benefit and complicating analysis.
- Failing to adjust for strata in the primary analysis — if stratification was used at randomization, omitting strata from the regression model wastes the precision gained and can bias variance estimates.
- Confusing blocking with blinding — blocking controls allocation balance; blinding controls information flow. Both are necessary and independent safeguards.
Frequently asked questions
What block size should I use?
Block size should be a multiple of the number of treatment arms (e.g., 4 or 6 for a two-arm trial). Smaller blocks enforce tighter balance but are more predictable; larger blocks are less predictable but tolerate more interim imbalance. Using randomly varying block sizes — alternating among, say, 2, 4, and 6 — is the most common practical compromise and is recommended by most regulatory guidance.
Is stratified block randomization the same as blocked randomization?
Stratified block randomization is blocked randomization applied separately within each stratum (e.g., each site or age group). Unstratified blocked randomization applies a single block sequence to all participants. Stratified blocking provides stronger guarantees of balance on the stratification variables and is recommended whenever those variables are strong prognostic factors.
Do I need to analyze blocked data differently?
Yes. If stratification variables were used in the randomization, they should appear as covariates in the primary analysis model (ANCOVA, logistic regression, or mixed model). Ignoring them in the analysis is a common protocol deviation flagged by regulators; it does not bias point estimates but reduces the precision advantage that stratification was meant to provide.
How is a blocked RCT different from a cluster RCT?
In a blocked RCT, individual participants within each block receive different treatments — the block is only an administrative grouping for randomization purposes. In a cluster RCT, all members of a cluster (e.g., a school or clinic) receive the same treatment; the cluster is the unit of randomization. These are fundamentally different designs with very different sample-size and analysis requirements.
When should I use minimization instead of blocking?
Minimization (covariate-adaptive randomization) is preferred over stratified blocking when there are many prognostic factors, or when the trial is small and perfectly balanced strata cannot be achieved. Minimization dynamically assigns the next participant to the arm that minimizes overall covariate imbalance. It requires a deterministic or near-deterministic allocation rule, so it demands strict central randomization and concealment.
Related methods
Sources
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2010). Fundamentals of Clinical Trials (4th ed.). Springer.
ISBN: 978-1441915856Copied.Pocock, S. J. (1983). Clinical Trials: A Practical Approach. Wiley.
ISBN: 978-0471901853Copied.